Cingulate (CING)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	6.12 mm	6.12 mm	6.12 mm	6.12 mm	6.12 mm	6.12 mm
Cash burn (monthly)	927.16 k	326.79 k	2.45 mm	1.85 mm	1.41 mm	1.48 mm
Cash used (since last report)	3.39 mm	1.19 mm	8.95 mm	6.75 mm	5.17 mm	5.40 mm
Cash remaining	2.73 mm	4.92 mm	-2.83 mm	-627.16 k	946.06 k	717.55 k
Runway (months of cash)	2.9	15.1	-1.2	-0.3	0.7	0.5

Beta Read what these cash burn values mean

Financial data from Cingulate earnings reports.

Institutional ownership, Q3 2024

CING institutional ownership history Ownership history

11.5% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	10	12	-16.7%
Opened positions	5	7	-28.6%
Closed positions	7	7	–
Increased positions	0	2	EXIT
Reduced positions	1	1	–

13F shares	Current	Prev Q	Change
Total value	27.15 mm	16.00 mm	+69.7%
Total shares	645.92 k	2.54 mm	-74.5%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Lind Global Fund II	282.00 k	$4.03 mm	0.0%
Hudson Bay Capital Management	210.80 k	$19.60 mm	0.0%
Peter J. Werth	98.03 k	$773.00 k	-91.7%
Shane J. Schaffer	40.39 k	$397.00 k	0.0%
Commonwealth Equity Services	11.28 k	$57.00 k	NEW
GoalVest Advisory	3.00 k	$207.00 k	0.0%
FMR	352.00	$1.77 mm	NEW
Advisor	55.00	$276.00 k	NEW
AlphaMark Advisors	10.00	$0.00	NEW
Headlands Technologies	7.00	$35.00 k	NEW

Largest transactions	Shares	Bought/sold	Change
Peter J. Werth	98.03 k	-1.08 mm	-91.7%
Sabby Management	0.00	-458.52 k	EXIT
Altium Capital Management	0.00	-270.00 k	EXIT
Warberg Asset Management	0.00	-43.16 k	EXIT
Armistice Capital	0.00	-20.50 k	EXIT
UBS UBS	0.00	-17.04 k	EXIT
Citadel Advisors	0.00	-13.36 k	EXIT
Commonwealth Equity Services	11.28 k	+11.28 k	NEW
FMR	352.00	+352.00	NEW
BAC Bank of America	0.00	-100.00	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CING insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
31 Dec 25	Raul R. Silva	Stock Option Common Stock	Grant	Acquire A	No	No	4.34	6,625	28.75 k	6,625
3 Nov 25	Bryan Wade Downey	Stock Option Common Stock	Grant	Acquire A	No	No	3.8	30,000	114.00 k	30,000
30 Sep 25	Raul R. Silva	Stock Option Common Stock	Grant	Acquire A	No	No	3.92	7,334	28.75 k	7,334

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Cingulate CEO Shane Schaffer Reinstated Following Legal Matter; Mr. Roberts To No Longer Serve As Executive Chairman Of The Board But Will Continue To Serve As Chairman

15 Dec 25

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed on August 14, 2025, the board of directors

Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $58

8 Dec 25

Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $62 to $58.

Roth Capital Maintains Buy on Cingulate, Lowers Price Target to $16

19 Nov 25

Roth Capital analyst Boobalan Pachaiyappan maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $17 to $16.

Cingulate's Data From Lead ADHD Candidate CTx-1301 Selected For Podium Presentation At AACAP Annual Meeting In Chicago

23 Oct 25

Press releases

From Benzinga Pro

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

23 Oct 25

KANSAS CITY, Kan., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary